In response to COVID-19, ACG takes measures to ensure workforce & public health

As a key pharma supply player, ACG is committed to working with its partners to ‘make the world healthier’. This means that of primary concern is the health of all people – around the world, and also in its own workplace.

So, in light of an escalation in the severity of the coronavirus pandemic – and effective immediately – ACG has mandated that wherever business functions allow, employees around the world should now work from home.

ACG is encouraging its staff to make use of all available IT solutions, and has committed to covering the associated expenses of working remotely. Furthermore, a company-wide ban on travel has been imposed, and participation at events and exhibitions suspended.

ACG has also taken proactive preventative measures to ensure the safety of factory bound workers, including daily screening with thermal scanners, providing easy access to sanitisers, and regular cleaning of all workspaces and commute buses. A crisis plan has also been developed in case an emergency situation arises.

In this time of medical crisis, and in support of its pharma partners, ACG has reaffirmed its commitment to providing uninterrupted supply of its products and services, and factories in all locations around the world are working at full capacity. The company has also taken proactive measures to ensure supply of its own raw materials for many months.

On the measures taken to fight COVID-19, Sunil Jha, Group CHRO of ACG said: “We are doing everything we possibly can to safeguard  the health of our associates and communities, while also ensuring our ability to honour commitments made to pharmaceutical customers in terms of meeting their increased requirements.

“These are unprecedented times calling for unprecedented measures, and we promise to stand strong alongside all healthcare providers fighting on the front lines of this pandemic.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Related news

Takeda opens R&D cell therapy manufacturing facility

Takeda is expanding its cell therapy manufacturing capabilities with the opening of a new 24,000 sq ft cell therapy manufacturing facility at its R&D...

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...